ArticleFrontiers in medicine2026
Early clinical outcomes after switching to faricimab in previously treated diabetic macular edema.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate short-term functional, anatomical, morphologic, and optical coherence tomography angiography (OCTA)-derived outcomes after switching to intravitreal faricimab in previously treated diabetic macular edema (DME) with persistent or recurrent center-involving retinal fluid after conventional anti-vascular endothelial growth factor therapy without angiopoietin-2 inhibition. Methods: This single-center retrospective study included 50 eyes from 50 patients with previously treated DME and center-involving intraretinal and/or subretinal fluid at the time of switching. All eyes received four consecutive monthly intravitreal faricimab injections. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were assessed through Month 4. OCT morphologic features were evaluated at baseline and Month 4, and OCTA-derived foveal avascular zone (FAZ) area, superficial capillary plexus vessel density (SCP-VD), and deep capillary plexus vessel density (DCP-VD) were evaluated at baseline, Month 1, and Month 4. Results: Mean CMT decreased from 526.8 ± 55.8 μm at baseline to 255.6 ± 20.5 μm at Month 4, while mean BCVA improved from 0.80 ± 0.19 to 0.28 ± 0.10 logMAR (both Conclusions: Faricimab switching followed by four consecutive monthly injections was associated with substantial short-term anatomical and visual improvement in previously treated DME with persistent or recurrent center-involving retinal fluid. Early clinical improvement occurred without parallel changes in global OCTA-derived perfusion parameters. Larger prospective controlled studies are needed to clarify the treatment-specific contribution and durability of faricimab switching.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.